Semaglutide 8mg Injection Pen Kit

£120.00

The Semaglutide 8mg Injection Pen Kit is a specially formulated product intended for scientific research on appetite control, metabolic processes, glucose signaling, and weight management strategies. This kit includes two pens, each containing 4mg of Semaglutide, totaling 8mg, which offers a comprehensive solution for laboratory research protocols.

As a recognized GLP-1 receptor agonist, Semaglutide is extensively researched for its role in suppressing appetite, managing energy balance, and regulating metabolism.

Each kit comes with two injection pens that allow for flexible dosing options of 0.25mg, 0.5mg, 0.75mg, and 1mg, enabling researchers to follow structured dosing protocols. The formulation is intended for administration once a week in research environments and operates through a GLP-1 agonist mechanism, making it an essential compound for studies related to obesity, appetite regulation, metabolic health, and glucose metabolism.

Category: WEIGHT LOSS

Description
Reviews (0)

Semaglutide 8mg Injection Pen Kit

Semaglutide 8mg Injection Pen Kit is a high-quality GLP-1 receptor agonist designed for scientific and laboratory research applications. This convenient 2-pen kit contains a total of 8mg of Semaglutide, supplied as two 4mg injection pens to support extended research protocols and long-term study requirements. Recognized as one of the most extensively researched GLP-1 compounds, Semaglutide is widely studied for its effects on appetite regulation, metabolic function, glucose control, energy balance, and weight management pathways.

The kit offers flexible dosing increments of 0.25mg, 0.5mg, 0.75mg, and 1mg, allowing researchers to implement controlled dosing schedules tailored to specific study objectives. With a once-weekly administration frequency, Semaglutide is frequently utilized in obesity, metabolic health, and GLP-1 receptor research throughout Europe and internationally.

Each Semaglutide 8mg Injection Pen Kit includes two injection pens delivering a combined total dose of 8mg. The compound acts through GLP-1 receptor agonism, making it a leading choice for investigations into appetite suppression, insulin response, body weight regulation, and metabolic science. Suitable for research use only, this formulation supports ongoing studies exploring the role of GLP-1 pathways in modern metabolic research.